Orin
CBTNYSE·Chemicals - Specialty

Cabot Corp. CBT

Market cap $4.1BP/E 21.8× trailingGross margin 22.9%Reports Mon 2 Nov, after the close
$78.80
−0.67 (−0.84%)Wed close 16:00 ET
52-wk $58.33 – $94.53
Watch
Orin's take
0.62conviction · moderate
Refreshed 20 Aug · take v5. A new filing or a print queues the next refresh.

Cabot Corp. remains a hold at $85.18, caught between improving margins and eroding earnings. FY2025 operating margin expanded to 16.7% from 15.4% and gross margin reached 25.3%, yet revenue fell 7% to $3.71B and adjusted EPS in Q3 FY2026 declined to $1.67 from $1.90 a year ago, with reported diluted EPS of just $0.12 due to sizable charges.

The EV/EBITDA of 7.86x trades at a 36% discount to the peer median of 12.19x, but the P/E of 23.6x sits at a 13% premium to peers, suggesting the market has already priced in margin recovery. A new $350M senior notes offering at 4.950% and the CEO transition add near-term uncertainty, while smart money flows are only marginally positive with fund count declining from 54 to 49.

What could go wrong

  • Earnings erosion. Q3 FY2026 adjusted EPS of $1.67 is down from $1.90 a year ago and reported diluted EPS was only $0.12 due to charges, signaling quality-of-earnings concerns.
  • Revenue decline. FY2025 revenue fell 7% to $3.71B from $3.99B, and Reinforcement Materials segment faces margin pressure that Performance Chemicals strength only partially offsets.
  • Increased leverage. New $350M senior notes at 4.950% due 2029 priced Aug 12, 2026 adds to existing total debt of $1.215B as of FY2025.
  • Leadership transition. CEO Sean Keohane exercised options and sold 91,923 shares at $86.41 on Aug 7, 2026, and his retirement introduces execution risk during battery materials capacity ramp.

What would change my mind

Revenue inflection. Quarterly revenue returns to positive YoY growth driven by battery materials demand and tire market recoverybullish
Margin compression. Operating margin falls below 15% as Reinforcement Materials pricing deteriorates faster than Performance Chemicals gainsbearish
Debt utilization clarity. Company specifies accretive use of proceeds from the $350M notes offering (acquisition vs. refinancing) that expands EBITDAbullish
Technical breakdown. Stock closes below the 200-day MA of $76.28 on rising volumebearish

Where this comes from: derived_metrics FY2025 · FMP fundamentals FY2025 · Q3 FY2026 earnings release (GlobeNewsWire 2026-08-03) · peer_relative composite. Orin's read on CBT; not advice.

Twelve months actual closes to 2026-09-23 · actual filings

Sept 25Nov 25Jan 26Mar 26May 26Jul 26

50-day average 200-day average · volume below

Largest holders · 13F Q2 2026

Money flow
FilerPositionOf fund
Earnest Partners$303.9M1.1% of fund
Vanguard Portfolio Management$279.4M0.0% of fund
Wellington Management Group Llp$219.5M0.0% of fund
Vanguard Capital Management$210.8M0.0% of fund
State Street$196.7M0.0% of fund
Geode Capital Management$161.6M0.0% of fund

57 filers · quarter ended Q2 2026 · positions, not flows

Insiders, last 24 months: 217 Form 4 filings, net $3.1M. Of the 50 on hand, 0 were open-market purchases and 3 sales— the rest are grants, option exercises and tax withholding.

Ask Orin about CBT

its filings · its transcripts · its numbers

Orin answers questions about CBT from its filings, transcripts and numbers — with the source behind every claim. Your own desk starts with 3 free days, card required.

Start 3 free days

Where it trades

· Basic Materials
MetricNowOwn medianSector
P/E21.8×29.8×
EV/EBITDA7.4×
P/S1.12×
P/B2.5×
What the price assumes

-1.3%

free-cash-flow growth every year for 10 years, discounted at 10%, is what today’s price implies — starting from $0.4B of trailing free cash flow. It is an assumption the market is making, not a forecast Orin is making.

What Wall Street published

15 firms · 2026-09-23
Consensus target

$94

$90$100 · +19% against today's price

How they rate it
  • 7 buy or overweight
  • 7 hold
  • 1 underweight or sell

The analysts’ consensus and their own ratings, not Orin’s. A target is a twelve-month opinion published by the firm that wrote it.

Against the companies it is compared to

median P/E 21.5× of 4 peers
CompanyMarket capP/EEV/EBITDAGrossNetROE
CBTCabot Corp.$4B21.8×7.4×22.9%5.2%12%
AVNTAvient Corporation$4B22.0×11.5×32.2%5.2%7%
CECelanese Corporation$5B93.0×20.2%-12.0%-29%
FULH.B. Fuller Company$3B14.7×9.1×32.5%5.3%9%
HWKNHawkins, Inc.$3B31.9×16.2×22.3%7.3%15%
KNFKnife River Corporation$3B20.9×10.4×17.9%4.2%9%
PRMPerimeter Solutions, Inc.$5B48.5%-44.9%-30%

The median is of the 4 peers listed above and nothing else — check it against the column. This company trades 1.7% above it. The peer set is the vendor’s, so a company can appear here that a person would not have chosen.

What it has traded at

P/E by fiscal year
FY14 16.3×FY25 12.5×

What its sector has traded at

Basic Materials
FY14 23.8×FY26 28.6×

Two scales, drawn separately on purpose: a sector median and one company’s multiple are not the same number and putting them on one axis invites a comparison neither series supports.

Every estimate on one scale

price $78.80
52-week range$58 – $95
Analyst targets$90 – $100
At sector P/E (30×)$108

The vertical rule is the current price. Ranges and point estimates are the backend’s, published as they were calculated; an arrow means the estimate sits beyond this scale, and its number is on the right.